Abstract
Treatment of human papillomavirus (HPV) oropharyngeal carcinomas requires a multidisciplinary approach as varied paradigms yield equally favorable oncologic outcomes. Adverse effects from the various treatment modalities can significantly affect quality of life differently and therefore have been important study endpoints in de-escalation trials. This presentation summarizes the management of oropharyngeal carcinomas and strategies to de-intensify treatment with a focus on the reduction of radiation dose. It will review the recent literature supporting the use of biomarkers including functional imaging, circulating HPV tumor DNA, and rapid mid-treatment nodal shrinkage to identify patients in which treatment can be safely de-escalated. Evidence suggests that there may be a group of patients that may benefit from de-escalation of treatment while maximally sparing organs at risk important for swallowing, speech, and salivary flow.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Head & Neck Physicians and Surgeons
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
